Total Payments
$1.7M
2024 Payments
$186,811
Companies
80
Transactions
2,826
Medicare Patients
3,463
Medicare Billing
$1.4M
Payment Breakdown by Category
Other$907,408 (54.3%)
Research$574,986 (34.4%)
Consulting$74,134 (4.4%)
Travel$69,191 (4.1%)
Food & Beverage$44,870 (2.7%)
Education$1,283 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $883,622 | 446 | 52.9% |
| Unspecified | $574,986 | 178 | 34.4% |
| Consulting Fee | $74,134 | 58 | 4.4% |
| Travel and Lodging | $69,191 | 338 | 4.1% |
| Food and Beverage | $44,870 | 1,731 | 2.7% |
| Honoraria | $23,700 | 19 | 1.4% |
| Education | $1,283 | 54 | 0.1% |
| Grant | $85.45 | 2 | 0.0% |
Payments by Type
General
$1.1M
2,648 transactions
Research
$574,986
178 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $330,224 | 148 | $0 (2023) |
| GENZYME CORPORATION | $296,326 | 426 | $0 (2023) |
| Ipsen Innovation | $154,956 | 120 | $0 (2024) |
| Biogen, Inc. | $126,913 | 242 | $0 (2024) |
| EMD Serono, Inc. | $110,296 | 181 | $0 (2024) |
| Amgen Inc. | $109,466 | 166 | $0 (2023) |
| Hoffmann-La Roche Limited | $91,800 | 11 | $0 (2024) |
| Genentech USA, Inc. | $77,914 | 87 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $72,439 | 230 | $0 (2024) |
| Allergan, Inc. | $71,436 | 151 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $186,811 | 145 | Ipsen Innovation ($154,956) |
| 2023 | $61,629 | 284 | Hoffmann-La Roche Limited ($17,261) |
| 2022 | $118,543 | 318 | Hoffmann-La Roche Limited ($43,246) |
| 2021 | $125,731 | 297 | Allergan, Inc. ($26,865) |
| 2020 | $136,454 | 286 | Allergan, Inc. ($19,363) |
| 2019 | $268,643 | 486 | GENZYME CORPORATION ($79,192) |
| 2018 | $240,043 | 433 | GENZYME CORPORATION ($69,750) |
| 2017 | $534,018 | 577 | Teva Pharmaceuticals USA, Inc. ($257,986) |
All Payment Transactions
2,826 individual payment records from CMS Open Payments — Page 1 of 114
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $2,254.56 | Research |
| Study: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants • Category: Neurology | ||||||
| 12/30/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $1,898.16 | Research |
| Study: Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants • Category: Neurology | ||||||
| 12/30/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $1,898.16 | Research |
| Study: Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants • Category: Neurology | ||||||
| 12/30/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $1,891.56 | Research |
| Study: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants • Category: Neurology | ||||||
| 12/30/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $1,891.56 | Research |
| Study: Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants • Category: Neurology | ||||||
| 12/30/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $1,891.56 | Research |
| Study: Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants • Category: Neurology | ||||||
| 12/30/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $1,754.28 | Research |
| Study: Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants • Category: Neurology | ||||||
| 12/30/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $881.76 | Research |
| Study: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants • Category: Neurology | ||||||
| 12/30/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $881.76 | Research |
| Study: Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants • Category: Neurology | ||||||
| 12/30/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $881.76 | Research |
| Study: Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants • Category: Neurology | ||||||
| 12/30/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $881.76 | Research |
| Study: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants • Category: Neurology | ||||||
| 12/30/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $881.76 | Research |
| Study: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants • Category: Neurology | ||||||
| 12/30/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $881.76 | Research |
| Study: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants • Category: Neurology | ||||||
| 12/30/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $881.76 | Research |
| Study: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants • Category: Neurology | ||||||
| 12/30/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $881.76 | Research |
| Study: Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants • Category: Neurology | ||||||
| 12/30/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $881.76 | Research |
| Study: Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants • Category: Neurology | ||||||
| 12/30/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $881.76 | Research |
| Study: Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants • Category: Neurology | ||||||
| 12/30/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $881.76 | Research |
| Study: Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants • Category: Neurology | ||||||
| 12/30/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $881.76 | Research |
| Study: Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants • Category: Neurology | ||||||
| 12/30/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $881.76 | Research |
| Study: Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants • Category: Neurology | ||||||
| 12/30/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $85.80 | Research |
| Study: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants • Category: Neurology | ||||||
| 12/30/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $85.80 | Research |
| Study: Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants • Category: Neurology | ||||||
| 12/04/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $2,199.00 | Research |
| Study: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants • Category: Neurology | ||||||
| 12/04/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $2,199.00 | Research |
| Study: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants • Category: Neurology | ||||||
| 12/04/2024 | Ipsen Innovation | Dysport (Drug) | — | Cash or cash equivalent | $2,199.00 | Research |
| Study: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants • Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TV48125-CNS-30049/50/51 | Teva Pharmaceuticals USA, Inc. | $185,880 | 4 |
| Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | Ipsen Innovation | $86,040 | 67 |
| A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants | Ipsen Innovation | $68,916 | 53 |
| TV48125-CNS | Teva Pharmaceuticals USA, Inc. | $61,368 | 6 |
| Fen Ph II RMS | Hoffmann-La Roche Limited | $48,554 | 6 |
| FEN PH II RMS | Hoffmann-La Roche Limited | $43,246 | 5 |
| IVSS US Local AED | SANOFI US SERVICES INC. | $23,433 | 1 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of Fremanezumab (TEV-48125) Versus Placebo for the Preventive Treatment of Chronic Migraine | Teva Pharmaceuticals USA, Inc. | $17,003 | 4 |
| PASS Lemtrada Local AED | SANOFI US SERVICES INC. | $9,750 | 8 |
| ACP-103-032 | ACADIA Pharmaceuticals Inc | $8,274 | 2 |
| Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) | EMD Serono, Inc. | $5,155 | 8 |
| 17-AVP-825-301 | Avanir Pharmaceuticals, Inc. | $4,500 | 2 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $3,236 | 3 |
| Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine | Teva Pharmaceuticals USA, Inc. | $3,026 | 1 |
| A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NBI-98854 IN PEDIATRIC SUBJECTS WITH TOURETTE SYNDROME | Neurocrine Biosciences, Inc. | $1,500 | 1 |
| A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multi | GENZYME CORPORATION | $1,500 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE - THE EVOLVE-1 STUDY | Eli Lilly and Company | $1,055 | 1 |
| FEN PH II RMS | F. Hoffmann-La Roche AG | $972.01 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE THE EVOLVE-1 STUDY | Eli Lilly and Company | $845.51 | 2 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH CHRONIC MIGRAINE - THE REGAIN STUDY | Eli Lilly and Company | $733.98 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 897 | 38,539 | $760,665 | $446,953 |
| 2022 | 12 | 877 | 37,844 | $746,005 | $429,987 |
| 2021 | 13 | 822 | 29,831 | $591,445 | $331,917 |
| 2020 | 15 | 867 | 21,468 | $439,130 | $220,961 |
Total Patients
3,463
Total Services
127,682
Medicare Billing
$1.4M
Procedure Codes
52
All Medicare Procedures & Services
52 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3032 | Injection, eptinezumab-jjmr, 1 mg | Office | 2023 | 32 | 14,400 | $288,000 | $191,883 | 66.6% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 41 | 22,700 | $175,925 | $112,469 | 63.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 325 | 561 | $109,395 | $53,804 | 49.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 163 | 332 | $43,160 | $22,894 | 53.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 151 | 151 | $45,300 | $18,832 | 41.6% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 34 | 110 | $22,000 | $14,057 | 63.9% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 29 | 29 | $18,125 | $9,667 | 53.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 42 | 130 | $19,500 | $7,314 | 37.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 40 | 45 | $11,925 | $6,029 | 50.6% |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Office | 2023 | 12 | 32 | $11,360 | $5,460 | 48.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 17 | 17 | $6,460 | $2,766 | 42.8% |
| 64405 | Injection of anesthetic agent and/or steroid into upper neck and back of head nerve | Office | 2023 | 11 | 32 | $9,515 | $1,778 | 18.7% |
| J3032 | Injection, eptinezumab-jjmr, 1 mg | Office | 2022 | 30 | 13,600 | $272,000 | $173,821 | 63.9% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 36 | 22,780 | $176,545 | $109,821 | 62.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 306 | 589 | $114,855 | $56,220 | 48.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 180 | 180 | $54,000 | $22,227 | 41.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 157 | 315 | $40,950 | $21,722 | 53.0% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2022 | 28 | 96 | $19,200 | $12,579 | 65.5% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2022 | 28 | 28 | $17,500 | $9,905 | 56.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 41 | 143 | $21,450 | $8,576 | 40.0% |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Office | 2022 | 13 | 37 | $12,980 | $6,607 | 50.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 30 | 37 | $9,805 | $5,050 | 51.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 12 | 12 | $4,560 | $2,301 | 50.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 16 | 27 | $2,160 | $1,160 | 53.7% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2021 | 34 | 21,800 | $168,815 | $104,964 | 62.2% |
About Dr. Jack Florin, MD
Dr. Jack Florin, MD is a Neurology healthcare provider based in Fullerton, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/29/2005. The National Provider Identifier (NPI) number assigned to this provider is 1912990656.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jack Florin, MD has received a total of $1.7M in payments from pharmaceutical and medical device companies, with $186,811 received in 2024. These payments were reported across 2,826 transactions from 80 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($883,622).
As a Medicare-enrolled provider, Florin has provided services to 3,463 Medicare beneficiaries, totaling 127,682 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 52 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Fullerton, CA
- Active Since 08/29/2005
- Last Updated 07/08/2007
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1912990656
Products in Payments
- Fremanezumab (Biological) $247,248
- AUBAGIO (Drug) $197,501
- Dysport (Drug) $154,975
- LEMTRADA (Drug) $95,621
- Aimovig (Biological) $91,970
- OCREVUS (Biological) $74,444
- GILENYA (Drug) $68,164
- BOTOX (Biological) $44,617
- Mavenclad (Biological) $36,812
- Mavenclad (Drug) $35,485
- UBRELVY (Drug) $33,269
- NO PRODUCT DISCUSSED (Drug) $33,183
- VYEPTI (Biological) $32,664
- VUMERITY (Drug) $32,367
- AJOVY (Drug) $31,014
- TECFIDERA (Drug) $30,201
- EMGALITY (Drug) $29,611
- TYSABRI (Biological) $26,660
- Rebif (Biological) $21,283
- ACTHAR (Biological) $16,722
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Fullerton
Dr. Johnson Moon, M.d, M.D
Neurology — Payments: $11,912
Neurology $11,912
Dr. Manpreet Multani, Md, MD
Neurology — Payments: $7,543
Neurology $7,543
Johanna Rosenthal, M.d, M.D
Neurology — Payments: $3,599
Neurology $3,599
Scott Turner, Md, MD
Neurology — Payments: $529.92
Neurology $529.92
Dr. Lowell Nelson, M.d., Ph.d, M.D., PH.D
Neurology
Neurology